Cargando…
Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
BACKGROUND: Non-small cell lung cancers (NSCLC) account for 85–90% of all lung cancers. As drug resistance critically impairs chemotherapy effectiveness, there is great need to identify new therapeutic targets. The aims of this study were to investigate the prognostic and therapeutic potential of th...
Autores principales: | Suraweera, Amila, Duff, Alex, Adams, Mark N., Jekimovs, Christian, Duijf, Pascal H. G., Liu, Cheng, McTaggart, Matthew, Beard, Sam, O’Byrne, Kenneth J., Richard, Derek J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434762/ https://www.ncbi.nlm.nih.gov/pubmed/32439936 http://dx.doi.org/10.1038/s41416-020-0899-2 |
Ejemplares similares
-
Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer
por: Suraweera, Amila, et al.
Publicado: (2021) -
COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target
por: Suraweera, Amila, et al.
Publicado: (2021) -
Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising
por: Jekimovs, Christian, et al.
Publicado: (2014) -
COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks
por: Suraweera, Amila, et al.
Publicado: (2021) -
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
por: Suraweera, Amila, et al.
Publicado: (2018)